While the molecular basis of the CHIP level-dependent differences in UPR will require future studies, the higher level of PERK activation in CHIP KD cells supports the idea that UPR induction by clinically used drugs could provide a potential approach to inhibit the growth of CHIP-low ErbB2-overexpressing tumor cells. Here, ERBB2 is linked to neoplasm.